Clinical Research Directory

Inclusion Criteria: * Men and women aged 18 and older; * Diagnosis of I-II b degree of ALI; * Patient consent to use reliable contraceptive methods throughout the study and for 3 weeks after: * women who have a negative pregnancy test and use the following contraceptives: intrauterine devices, oral contraceptives, contraceptive patch, prolonged injectable contraceptives, double barrier method of contraception. Women who are not fertile can also take part in the study (documented conditions: hysterectomy, tubal ligation, infertility, menopause for more than 1 year); * men using barrier contraception. The study may also involve men who are not fertile (documented conditions: vasectomy, infertility); * Availability of signed and dated informed consent of the patient to participate in the study. Exclusion Criteria: * Extensive bleeding at present; * Intracranial (including subarachnoid) hemorrhage at present; * Recent gastrointestinal bleeding (within 10 days); * Major surgery or major trauma within the previous 3 months, recent traumatic brain injury; * Systolic blood pressure above 180 mm Hg or diastolic blood pressure above 110 mm Hg or the need for intravenous drugs to lower blood pressure to these limits; * Pregnancy, lactation; * Known hypersensitivity to Fortelyzin®; * Platelet count less than 100,000/µL